GHRP-6 PEPTIDE (GROWTH HORMONE RELEASING PEPTIDE 6) 5MG/10MG VIAL
$25.99 – $40.99
GHRP-6 is sold for laboratory research use only. Terms of sale apply. Not for human consumption, nor medical, veterinary, or household uses. Please familiarize yourself with our Terms & Conditions prior to ordering.
- Additional information
|Purity||≥99% Pure (LC-MS)|
|Storage||Store in a dry, cool, dark place. For best preservation, store at 4°C or colder away from bright light.|
|Terms||Lab Use Only. This information is for educational purposes only and does not constitute medical advice.|
GHRP-6 is a growth hormone-releasing peptide that has been shown to release growth hormone (GH) in vivo in several different species. A study conducted by Rico et. Al, studied the effects of GHRP-6 in vitro in bovine somatotropes that were separated through elutriation. GHRP-6 was administered in doses from 10(-8) M to 10(-5)M as well as 10(-9)M in the pituitary cells of the cows. It was found that all doses stimulated the release of GH, however, maximal stimulation of GH was found at 10(-6)M. The effects of treatment with GHRP-6 were seen at hours 1, 2, 3, and 4 of incubation, with the exception of heifer pituitary cells which did not experience the effects at hour 1 of the incubation period (https://pubmed.ncbi.nlm.nih.gov/10494658/).
Effects of GHRP-6 in Preventing Cardiovascular Failure
Several studies in mice conducted from 1997 to 1999 examined the role that growth hormone-releasing peptides played in preventing heart failure. These studies were limited due to technology and resources but came to the general conclusion that GHRPs were able to prevent cardiovascular failure.
In more recent studies DCM models characterized by left ventricle dilation, wall thinning, and systolic dysfunction examine how GHRP-6 was able to combat the declining function of the left ventricle. Rats were administered doxorubicin (DX) in order to induce a DCM model of heart failure. Overall, the study found that rats treated with GHRP-6 experienced a complete prevention of heart failure and decreased mortality rate among the rats.
While it is still difficult to determine exactly why GHRP-6 is able to prevent heart failure and increase survival rate, a report by Merck Research Laboratories theorized that this occurred due to the mediation of Ca2+. When Ca2+ is triggered to release from intracellular stores there is a resulting positive inotropic effect without the possibility of eliciting a drastic change in heart rate.
GHRP-6 and Heart Health
Furthermore, a study conducted by Berlanga-Acosta et. Al, treated both infarcted and healthy rabbits with GHRP-6 in order to examine the effects the peptide had on the heart. Researchers treated the rabbits with 400 microg/kg of GHRP-6 through an intravenous bolus. Similar to the theory mentioned above, it was found that treatment with GHRP-6 led to a positive and transient inotropic effect on the cardiac muscle. Additionally, the study showed that when treated with GHRP-6 the ejection fraction increased by 15-20% which was confirmed through the use of echocardiography.
Belanga-Acosta et. Al conducted a similar study using porcine models that had undergone acute myocardial infarction caused by blocking the left circumflex artery. The subjects were then reperfused over a 72-hour period and it was shown that the treatment led to a reported repair of the damaged myocardium (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5392015/)
Peptides Prefer the Cold
In order to reduce peptide breakdown, keep peptides refrigerated at all times but DO NOT FREEZE.
Swab the top of the vial with a 95% alcohol wipe before accessing.
Only Mix with Sterile Bacteriostatic Water
Bacteriostatic water is vital to preventing contamination and preserving the stability of the compound.
Push the needle through the stopper at an angle in order to direct the stream to the side of the vial.
Reconstituted peptide solution should be stored at around 4 degrees Celsius but not frozen, while lyophilized peptide solution should be kept at -20 degrees Celsius.
Growth hormone-releasing peptide 6 (GHRP-6) (developmental code name SKF-110679), also known as growth hormone-releasing hexapeptide, is one of several synthetic met-enkephalin analogues that include unnatural D–amino acids, were developed for their growth hormone-releasing activity and are called growth hormone secretagogues. They lack opioid activity but are potent stimulators of growth hormone (GH) release. These secretagogues are distinct from growth hormone releasing hormone (GHRH) in that they share no sequence relation and derive their function through activation of a completely different receptor. This receptor was originally called the growth hormone secretagogue receptor (GHSR), but due to subsequent discoveries, the hormone ghrelin is now considered the receptor’s natural endogenous ligand, and it has been renamed as the ghrelin receptor. Therefore, these GHSR agonists act as synthetic ghrelin mimetics.
NEVER SHAKE A VIAL TO MIX.
**LAB USE ONLY**
*This information is for educational purposes only and does not constitute medical advice. THE PRODUCTS DESCRIBED HEREIN ARE FOR RESEARCH USE ONLY. All clinical research must be conducted with oversight from the appropriate Institutional Review Board (IRB). All preclinical research must be conducted with oversight from the appropriate Institutional Animal Care and Use Committee (IACUC) following the guidelines of the Animal Welfare Act (AWA).